Dr Elise Kohn
Dr. Kohn’s focus is to review, coordinate, and oversee development and execution of scientifically driven and practice-changing trials phase II-III clinical trials in gynecologic cancers and gastrointestinal neuroendocrine cancers. She provides disease and translational science expertise for drug development and clinical trials planning. Dr. Kohn also applies her expertise to the oversight and guidance of the NCTN Core Correlative Science Committee, which reviews proposals for correlative science projects using annotated clinical trial biospecimens. She continues to see and supervise targeted therapy clinical trial gynecologic cancer patient care in the Women’s Cancers Clinic that she initiated twenty years ago. Dr. Kohn spent over 2 decades overseeing a laboratory and clinical program in the National Cancer Institute intramural program focused on signal transduction molecular targets in invasion, metastasis, and angiogenesis, and proteomic applications, applied towards ovarian cancers. Her clinical program focused on application of novel agents and translational opportunities to women’s cancers, especially ovarian cancer, via phase 1 and 2 studies. Dr. Kohn serves on SGO and ASCO Education Committees, and has completed a tour on the integration panel of the Department of Defense Ovarian Cancer Research Program, on which she also served as panel chair. Dr. Kohn has received the Ovarian Cancer National Alliance’s Rosalind Franklin Excellence in Ovarian Cancer Research Award, NIH Director’s Merit Awards, Diversity and Mentoring Awards. Dr. Kohn was elected a Fellow of the American Association for the Advancement of Science in 2002.